Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Albiger, 2015, Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015, Euro Surveill, 20, 10.2807/1560-7917.ES.2015.20.45.30062

2016

Zusman, 2013, Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems, Antimicrob Agents Chemother, 57, 5104, 10.1128/AAC.01230-13

Paul, 2014, Combination therapy for carbapenem-resistant Gram-negative bacteria, J Antimicrob Chemother, 69, 2305, 10.1093/jac/dku168

Schwaber, 2008, Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality, Antimicrob Agents Chemother, 52, 1028, 10.1128/AAC.01020-07

Muggeo, 2017, Factors associated with carriage of carbapenem-non-susceptible Enterobacteriaceae in North-Eastern France and outcomes of infected patients, J Antimicrob Chemother, 72, 1496, 10.1093/jac/dkw590

Dickstein, 2016, Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol, BMJ Open, 6, e009956, 10.1136/bmjopen-2015-009956

Garonzik, 2011, Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients, Antimicrob Agents Chemother, 55, 3284, 10.1128/AAC.01733-10

Paul, 2010, Effectiveness and safety of colistin: prospective comparative cohort study, J Antimicrob Chemother, 65, 1019, 10.1093/jac/dkq069

Deeks

Zusman, 2017, Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis, J Antimicrob Chemother, 72, 29, 10.1093/jac/dkw377

Qureshi, 2012, Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens, Antimicrob Agents Chemother, 56, 2108, 10.1128/AAC.06268-11

Daikos, 2014, Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems, Antimicrob Agents Chemother, 58, 2322, 10.1128/AAC.02166-13

Tumbarello, 2015, Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study, J Antimicrob Chemother, 70, 2133, 10.1093/jac/dkv086

Kengkla, 2018, Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis, J Antimicrob Chemother, 73, 22, 10.1093/jac/dkx368

Durante-Mangoni, 2014, Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date, Future Microbiol, 9, 773, 10.2217/fmb.14.34

Karaiskos, 2015, Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients, Antimicrob Agents Chemother, 59, 7240, 10.1128/AAC.00554-15

Plachouras, 2009, Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria, Antimicrob Agents Chemother, 53, 3430, 10.1128/AAC.01361-08

Nicolau, 2008, Pharmacokinetic and pharmacodynamic properties of meropenem, Clin Infect Dis, 47, S32, 10.1086/590064

Nutman, 2014, A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia, Clin Microbiol Infect, 20, O1028, 10.1111/1469-0691.12716

Principe, 2014, Epidemic diffusion of OXA-23-producing Acinetobacter baumannii isolates in Italy: results of the first cross-sectional countrywide survey, J Clin Microbiol, 52, 3004, 10.1128/JCM.00291-14

Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253

Shields, 2017, Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia, Antimicrob Agents Chemother, 61, e008833, 10.1128/AAC.00883-17

2017

Faden, 2014, Informed consent, comparative effectiveness, and learning health care, N Engl J Med, 370, 766, 10.1056/NEJMhle1313674